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The formation of blood clots in blood vessels causes severe ischemic diseases such as cerebral infarction
and myocardial infarction. While searching for microbial products that increase fibrinolytic activity using
an in vitro fibrin degradation assay, we found malformin A1, a disulfide form of cyclo(–D-Cys-D-Cys-L-Val-
D-Leu-L-Ile–), as an active compound. In this study, we synthesized malformin derivatives using a solid-
phase peptide synthesis method and evaluated their fibrinolytic activity and cytotoxicity. Reduction of
the disulfide bond and linearization of the cyclic peptide frame decreased the pro-fibrinolytic activity.
Substitution of a branched-chain amino acid with lysine resulted in loss of activity. However, protection
of the amino group in the lysine derivatives by the tert-butoxycarbonyl (Boc) group rescued the inactiv-
ity. Furthermore, the phenylalanine derivatives also exhibited a similar pro-fibrinolytic effect compared
to malformin A1. These results suggest that the disulfide bond, the cyclic peptide frame, and the bulky
hydrophobic side chains play a crucial role in the pro-fibrinolytic activity of malformin. The effective dose
of the active derivatives for the in vitro fibrin degradation showed similar ranges (1–5 lM), while the
order of cytotoxic potency for the active derivatives was as follows: Phe-derivatives > BocLys-deriva-
tives > malformin A1 > reduced form. These results showed no correlation between pro-fibrinolytic activ-
ity and cytotoxicity, suggesting the possibility of the synthesis for non-toxic malformin derivatives
possessing the activity.
 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Irregular thrombus formation causes severe ischemic diseases nase-type plasminogen activator (uPA), are available for the treat-
such as stroke or heart attack. Antithrombotic therapies are catego-
rized into three groups: anticoagulants, antiplatelet agents, and
thrombolytics. A thrombolytic therapy induces the conversion of
proenzyme plasminogen, a proenzyme, to plasmin, a fibrinolytic
enzyme, which in turn leads to the degradation of insoluble fibrin,
the main component of thrombus. Although thrombolytic
enzymes, such as tissue-type plasminogen activator (tPA) or uroki-ment of thrombotic disorders, a low molecular weight compound
that can enhance fibrinolytic activity is an unmet medical require-
ment for thrombolytic therapies. In particular, oral drugs that can
reduce the formation of fibrin clots would be beneficial in prevent-
ing thrombotic disorders.
While searching for natural products that could increase fibri-
nolytic activity, we found malformin A1 (MA1) 1, a disulfide form
of cyclo(–D-Cys-D-Cys-L-Val-D-Leu-L-Ile–), as an active compound
(Fig. 1A).1 1 was originally identified as a fungal metabolite that
induces curvature and malformations in bean plants, and curva-
tures in corn roots.2–5 Thereafter, the various biological activities
of 1, such as anti-bacterial activity,6 anti-tobacco mosaic virus
activity,7 anti-protozoan activity against Plasmodium and
Trypanosoma,8 anti-proliferative activity against cancer cell
lines,9,10 and suppression of interleukin 1b-induced tissue factor
expression,11 have been reported. Furthermore, several types of
natural analogs of 1 in which D-Leu or L-Ile was substituted with
another branched-chain amino acid are known.12,13 Among them,
malformin C, also termed malformin A3 or malformin B1b, in
Figure 1. Malformin A1. (A) Structure of malformin A1 (1). (B) Effects of natural and synthetic malformin A1 (1) on an in vitro fibrin degradation assay. U937 cells in RPMI-
1640 medium supplemented with human platelet-poor plasma were added to each well of the 125I-fibrin-coated 96-well plate. After incubation for 3 h with malformin
derivatives at the indicated concentration, 125I-fibrin degradation products released into the supernatant were quantified using a c-counter. Data are presented as means ± SD
(n = 3). *p <0.05, **p <0.01, versus control.
Scheme 1. Solid-phase synthesis of malformin A1 (1). Reagents and conditions: (a) (i) Fmoc-D-Leu-OH, DIPEA, DCM, rt, 1 h; (ii) 2% DBU/DMF, rt, 5 min  3; (b) (i) Fmoc-L-Val-
OH, PyBOP, DIPEA, DCM/DMF (4:1), rt, 1 h; (ii) 2% DBU/DMF, rt, 5 min  3; (c) (i) Fmoc-D-Cys(S-Trt)-OH, DIPCI, HOBt, DCM/DMF (4/1), rt, 1 h; (ii) 2% DBU/DMF, rt, 5 min  3;
(d) (i) Fmoc-D-Cys(S-Trt)-OH, DIPCI, HOBt, DCM/DMF (4:1), rt, 1 h; (ii) 2% DBU/DMF, rt, 5 min  3; (e) (i) Fmoc-L-Ile-OH, PyBOP, DIPEA, DCM/DMF (4:1), rt, 1 h; (ii) 2% DBU/
DMF, rt, 5 min  3; (f) 20% HFIP/DMF, rt, 30 min; (g) HATU, DIPEA, DMF (0.01 M), rt, 3 h; (h) I2, DMF, rt, 30 min. DIPEA = N,N-diisopropylethylamine, DCM = dichloromethane,
DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene, DMF = N,N-dimethylformamide, PyBop = benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate, DIPCI = N,
N-diisopropylcarbodiimide, HOBt = 1-hydroxy-1H-benzotriazole, HFIP = 1,1,1,3,3,3-hexafluoro-2-propanol, HATU = O-(7-aza-1H-benzotriazol-1-yl)-N,N,N0 ,N0-tetramethy-
luronium hexafluorophosphate.
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ber of biological activities.8,14–18
The mode of action of 1 in enhancing the fibrinolytic activity
involves the plasminogen/uPA system, and depends on the coordi-
nated action of vitronectin as a plasma component and an
unknown mechanism in monocytoid cells.1,19 In this study, for
the purpose of increasing pro-fibrinolytic activity, decreasing
cytotoxicity, and designing a chemical probe to identify the molec-
ular target(s) of 1, we synthesized malformin derivatives using a
solid-phase peptide synthesis method and evaluated the efficacy
of these derivatives on in vitro fibrin degradation and cytotoxicity.
Syntheses of malformin and its analogs have already been
reported.5,8,20 O¯mura’s group reported an elegant route to mal-
formin C synthesis via resin-bound macrolactamization and disul-
fide bond formation together with cleavage from the resin.8
However, the yield of the cyclic peptide was relatively low, because
of undesired interactions with the resin in the final oxidation step.
Thus, our synthetic strategy involved a solid-phase peptide synthe-
sis of a linear precursor, followed by macrolactamization, and an
oxidative disulfide formation in liquid-phase synthesis. Synthesis
of 1 is shown in Scheme 1. Fmoc-D-Leu-OH was anchored to a
2-chlorotrityl chloride resin and the Fmoc group was removed bytreatment with 2% DBU/DMF to produce a resin-anchored amino
acid 2. The loading yield was estimated at 97% by determining
the quantity of dibenzofulvene generated from the Fmoc group.21
The remaining four amino acids were introduced to prepare a lin-
ear pentapeptide 3. Coupling of Fmoc-L-Val-OH and Fmoc-L-Ile-OH
were accomplished using PyBop and DIPEA. For the coupling of
Fmoc-D-Cys(S-Trt)-OH, DIPCI and HOBt were used.22 Cleavage from
the 2-chlorotrityl resin with 20% HFIP/DCM released linear peptide
4,23 which was cyclized using HATU under high dilution conditions
(0.01 M) to produce the cyclic peptide 5 in 67% yield. Finally, the
cyclic peptide was subjected to an iodine-induced oxidative disul-
fide bond formation to produce 1 in 65% yield. The 1H and 13C NMR
spectra, optical rotation, IR, and high-resolution MS were in com-
plete accord with those of the natural product. New malformin
derivatives substituted with various L- and D-amino acids were
prepared by the same synthetic process (Table 1).
Evaluation of the effects of synthesized malformin derivatives
on fibrinolytic activity was performed using an in vitro fibrin
degradation assay system.1,19 Synthetic 1 caused an enhanced
fibrin degradation in the same dose-dependent manner as natu-
ral 1, indicating that the synthesis of 1 has been successful
(Fig. 1B).
Table 1
Amino acid building blocks and cytotoxicities of synthesized malformin derivatives
Compounds Amino acids Viability
aa1 aa2 aa3 aa4 aa5 IC50 (lM)
1 (natural)a D-Cys D-Cys L-Val D-Leu L-Ile 0.80
1 (synthetic)a D-Cys D-Cys L-Val D-Leu L-Ile 0.76
5 D-Cys(S-Trt) D-Cys(S-Trt) L-Val D-Leu L-Ile >5
6 D-Cys(S-Me) D-Cys(S-Me) L-Val D-Leu L-Ile >5
7b D-Cys D-Cys L-Val D-Leu L-Ile >5
8c D-Cys D-Cys — — — >5
9d D-Cys D-Cys L-Val D-Leu L-Ile >5
10a D-Cys D-Cys L-Ala D-Leu L-Ile 1.4
11a D-Cys D-Cys L-Val D-Ala L-Ile 2.2
12a D-Cys D-Cys L-Val D-Leu L-Ala 2.8
13a D-Cys D-Cys L-Lys D-Leu L-Ile >5
14a D-Cys D-Cys L-Val D-Lys L-Ile >5
15a D-Cys D-Cys L-Val D-Leu L-Lys >5
16a D-Cys D-Cys L-Lys(Ne-Boc) D-Leu L-Ile 0.1>
17a D-Cys D-Cys L-Val D-Lys(Ne-Boc) L-Ile 0.20
18a D-Cys D-Cys L-Val D-Leu L-Lys(Ne-Boc) 0.1>
19a D-Cys D-Cys L-Phe D-Leu L-Ile 0.1>
20a D-Cys D-Cys L-Val D-Phe L-Ile 1.3
21a D-Cys D-Cys L-Val D-Leu L-Phe 0.1>
a Disulfide form of cyclic pentapeptide.
b Reduced form of cyclic pentapeptide.
c Disulfide form of dipeptide.
d Disulfide form of linear pentapeptide (aa5–aa1–aa2–aa3–aa4).
Figure 2. Effects of disulfide bond-modified malformin derivatives (5–7) cysteinyl-
cysteine disulfide (8), and linear malformin A1 (9) on an in vitro fibrin degradation
assay. The experimental procedure is the same as Figure 1B.
Figure 3. Effects of alanine-substituted malformin derivatives (10–12) on an
in vitro fibrin degradation assay. The experimental procedure is the same as
Figure 1B.
Y. Koizumi et al. / Bioorg. Med. Chem. Lett. 26 (2016) 5267–5271 5269Next, to confirm the involvement of the disulfide bond in the
pro-fibrinolytic activity of 1, we synthesized disulfide bond-modi-
fied derivatives (Fig. 2). Both bulky trityl derivatives (TrtMA1, 5)
and unbulky methyl derivatives (MeMA1, 6) did not demonstrate
pro-fibrinolytic activity. The reduced form (RedMA1, 7) showed
no significant change up to 10 lM, but increased the degradation
activity at more than 20 lM. These results indicate that the disul-
fide bond in 1 is essential for pro-fibrinolytic activity. Next, we
checked for the activity of D-cysteinyl-D-cysteine disulfide (CCDS,
8) as a minimum dipeptide unit containing disulfide bonds
(Fig. 2). Addition of 8 showed no enhancement in fibrinolytic activ-
ity, suggesting that a longer peptide structure containing a disul-
fide bond is required for pro-fibrinolytic function. However, a
linear form of 1 (LinMA1, 9) had no activity (Fig. 2). These results
indicate that not only the disulfide bond but also the cyclic peptide
frame in malformins is necessary for pro-fibrinolytic activity.
Next, we applied alanine-scanning to determine the contribu-
tion of a specific amino acid to the pro-fibrinolytic effect of 1(Fig. 3). Alanine-substitution at L-Val (3-AlaMA1, 10) resulted in
an approximately 2-fold lower specific activity than 1, whereas a
substitution at D-Leu and L-Ile (4-AlaMA1, 11 and 5-AlaMA1, 12,
respectively) only resulted in a slight increase in fibrin degrada-
tion. These results indicate that the bulkiness at the three
branched-chain amino acids’ position in 1 plays a key role in
pro-fibrinolytic activity.
As the above results demonstrated the significance of bulky
amino acid moieties, we synthesized two types of bulky amino
acid-derivative substituted by lysine and Ne-tert-butoxycarbonyl
lysine (LysMA1s, 13–15 and BocLysMA1s, 16–18, respectively),
and evaluated their effects on fibrinolytic activity (Fig. 4). Lysine-
substitution of branched-chain amino acids in 1 resulted in a loss
of activity, while Boc protection of the e-amino group in 13–15
restored their activity. Moreover, phenylalanine-substitution of
branched-chain amino acids in 1 (PheMA1s, 19–21) exhibited a
similar effect compared with 1 (Fig. 5). These results indicate that
Figure 4. Effects of lysine- or Ne-tert-butoxycarbonyl lysine-substituted malformin derivatives (13–18) on an in vitro fibrin degradation assay. The experimental procedure is
the same as Figure 1B.
Figure 5. Effects of phenylalanine-substituted malformin derivatives (19–21) on an
in vitro fibrin degradation assay. The experimental procedure is the same as
Figure 1B.
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fibrinolytic activity of 1.
Finally, we evaluated the cytotoxicity of malformin derivatives
against U937 cells (Fig. 6 and Table 1). Natural 1 and synthetic 1
showed almost the same cytotoxicity with IC50 values of 0.80
and 0.76 lM, respectively. Disulfide bond-modified derivatives 5
and 6 had no cytotoxic effects (with IC50 values of >5.0 lM), similar
to their in vitro fibrinolytic activity. The reduced form 7 exhibited a
slight cytotoxicity but its IC50 value was >5.0 lM. The dipeptide 8
had no cytotoxic effect up to 5.0 lM, whereas the linear pentapep-
tide 9 had only a modest cytotoxic effect although its IC50 value
was >5.0 lM. The Ala-derivatives 10, 11, and 12 exhibited weaker
cytotoxicities than 1 (with IC50 values of 1.4, 2.2, and 2.8 lM,
respectively). The Lys-derivatives 13, 14, and 15 did not show
any cytotoxic effect, as observed in their in vitro fibrinolytic activ-
ity. In contrast to the Lys-derivatives, the BocLys-derivatives 16,
17, and 18 showed potent cytotoxicities with IC50 values of
<0.10, 0.20, and <0.10 lM, respectively. Among the Phe-deriva-
tives, both 19 and 21 exhibited high potent cytotoxic effects with
IC50 values of <0.10 lM, whereas the 20 had a weaker cytotoxicity
compared than that of 1 (with IC50 values of 1.3 lM).In the present study, the pro-fibrinolytic activity of the reduced
form 7 was decreased by about 1/10 as compared with that of 1,
indicating that the disulfide bond in 1 is essential for pro-fibri-
nolytic activity. The importance of disulfide bond formation in the
bioactivity of malformins has been reported.24–26 Isono et al.
observed that the reductively benzylating form of 1 was inactive,
and that the reduced form of 1 possessed 1/10 of the biological
activity of 1 in the corn-root curvature assay.24 Iriuchijima et al.
indicated that 1:1 addition products of 1with cysteine or 2-mercap-
toethanol decreased the biological activity in the same assay.25
Moreover, a reduced form of malformin C has also been reported
to have a lower anti-protozoan activity against Plasmodium and
Trypanosoma.8 We postulate that weaker activity of reduced form
7 is due to its instability in extracellular condition or to prevention
of membrane trafficking of 7 by interaction with plasma compo-
nents. FK228, a histone deacetylase inhibitor, is a depsipeptide con-
taining intramolecular disulfide bonds.27 The disulfide bonds of
FK228 are reduced in intracellular reducing environment, and are
considered to interact with the active-site zinc in histone deacety-
lase.28 Both results that disulfide bond-modified derivatives 5 and 6
have no activities and that reduced form 7 possesses aweak activity
in the presence of plasma component are similar to the character-
istics of FK228.28 Hence, 1 may also act as a prodrug and may be
converted into a reduced form that can interact with a target mole-
cule by intracellular reducing activity such as glutathione.
Even though the disulfide bond of 1 is required for pro-fibri-
nolytic activity, linear pentapeptides comprising of disulfide bonds
had no activity. These results indicate that a rigid bicyclic structure
consisting of both a cyclic peptide and a disulfide bond is essential
for the activity. Furthermore, the side chain(s) of the amino acids
constituting the cyclic peptide frame also seem to play a crucial
role. A decline in the pro-fibrinolytic activity after any alanine-sub-
stitution of a branched-chain amino acid suggests that a bulky
amino acid is required for activity. Substitution with a more bulky
Ne-tert-butoxycarbonyl lysine or phenylalanine retained the
ability to enhance cellular fibrinolysis, indicating that a steric
hindrance at these bulky sites during the interactions with target
molecule(s) is unlikely to occur. Moreover, a lysine-substitution
to impart hydrophilicity resulted in loss of activity, suggesting that
the target molecule of 1 is localized in intracellular compartment.
Unlike the pro-fibrinolytic activity, the cytotoxicity was greatly
influenced by the amino acid substitution. While the active
Figure 6. Cytotoxic effects of malformin derivatives in U937 cells. U937 cells were treated with malformin derivatives at indicated doses for 24 h. The cytotoxicity was
evaluated using an MTT assay. (A) Synthetic malformin A1 (1) and disulfide bond-modified malformin derivatives (5–7). (B) Cysteinyl-cysteine disulfide (8) and linear
malformin A1 (9). (C) Alanine-substituted malformin derivatives (10–12). (D) Lysine-substituted malformin derivatives (13–15). (E) Ne-tert-Butoxycarbonyl lysine-
substituted malformin derivatives (16–18). (F) Phenylalanine-substituted malformin derivatives (19–21). Data are presented as means ± SD (n = 3).
Y. Koizumi et al. / Bioorg. Med. Chem. Lett. 26 (2016) 5267–5271 5271derivatives of 1 showed similar effective dose ranges in the in vitro
fibrin degradation assay system (1–5 lM), the order of cytotoxicity
for the active derivatives was as follows:
Phe-derivatives > BocLys-derivatives > MA1 > Ala-deriva-
tives reduced form
These results showed no correlation between pro-fibrinolytic
activity and cytotoxicity, suggesting that the synthesis of non-toxic
malformin derivatives with a pro-fibrinolytic function is possible.
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